Huttunen 1995.
Methods | Allocation: randomised (no further description). Blindness: double (no further description). Duration: 6 weeks. Consent: given. Setting: multicentre. | |
Participants | Diagnosis: schizophrenia (DSM‐III‐R). N=98. Sex: 47M, 51F. Age: 11‐43 years, mean ˜ 36 years. History: chronic, currently acutely ill. | |
Interventions | 1. Risperidone: 2‐20 mg/day, dose decided by clincial judgement. N=48. 2. Zuclopenthixol: 10‐100mg/day, dose decided by clincial judgement. N=50. | |
Outcomes | Clinical improvement: 20% reduction in PANSS.
Comparison with previous medication: Categorical scale.
Adverse effects: use of antiparkinson medication, other various observed effects.
Leaving the study early. Unable to use ‐ Global effect: CGI (no SD). Mental state: PANSS, BPRS ‐ PANSS derived (no SD). Physiological monitoring: ECG, lab tests (no data). Adverse effects: ESRS, UKU (no SD). |
|
Notes | ||
Risk of bias | ||
Bias | Authors' judgement | Support for judgement |
Allocation concealment? | Unclear risk | B ‐ Unclear |